Genfit (GNFT) Revenue & Revenue Breakdown
Genfit Revenue Highlights
Latest Revenue (Y)
$28.57M
Latest Revenue (Q)
$17.08M
Genfit Revenue by Period
Genfit Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $28.57M | 41.45% |
| 2022-12-31 | $20.20M | -74.78% |
| 2021-12-31 | $80.07M | 10366.54% |
| 2020-12-31 | $765.00K | -97.52% |
| 2019-12-31 | $30.84M | 44594.20% |
| 2018-12-31 | $69.00K | -41.53% |
| 2017-12-31 | $118.00K | -58.45% |
| 2016-12-31 | $284.00K | -46.11% |
| 2015-12-31 | $527.00K | -67.36% |
| 2014-12-31 | $1.61M | -15.00% |
| 2013-12-31 | $1.90M | 13.57% |
| 2012-12-31 | $1.67M | -29.17% |
| 2011-12-31 | $2.36M | -37.17% |
| 2010-12-31 | $3.76M | -35.35% |
| 2009-12-31 | $5.81M | -33.66% |
| 2008-12-31 | $8.76M | -7.56% |
| 2007-12-31 | $9.48M | -5.72% |
| 2006-12-31 | $10.05M | -21.31% |
| 2005-12-31 | $12.77M | - |
Genfit generated $28.57M in revenue during NA 2023, up 41.45% compared to the previous quarter, and up 41398.55% compared to the same period a year ago.
Genfit Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $17.08M | 506.21% |
| 2023-09-30 | $2.82M | -75.46% |
| 2023-06-30 | $11.48M | 51.96% |
| 2023-03-31 | $7.56M | 23.97% |
| 2022-12-31 | $6.09M | 14.78% |
| 2022-09-30 | $5.31M | -39.59% |
| 2022-06-30 | $8.79M | 44.79% |
| 2022-03-31 | $6.07M | -92.42% |
| 2021-12-31 | $80.06M | 95.02% |
| 2021-09-30 | $41.05M | 373090.91% |
| 2021-06-30 | $11.00K | -99.32% |
| 2021-03-31 | $1.63M | 153.03% |
| 2020-12-31 | $643.00K | -54.32% |
| 2020-09-30 | $1.41M | 1053.69% |
| 2020-06-30 | $122.00K | -95.84% |
| 2020-03-31 | $2.93M | -90.49% |
| 2019-12-31 | $30.84M | 83.47% |
| 2019-09-30 | $16.81M | 1680700.00% |
| 2019-06-30 | $1.00K | -99.96% |
| 2019-03-31 | $2.68M | 144.65% |
| 2018-12-31 | $1.09M | -10.62% |
| 2018-09-30 | $1.22M | -51.49% |
| 2018-06-30 | $2.52M | - |
| 2018-03-31 | $2.52M | 125.57% |
| 2017-12-31 | $1.12M | - |
| 2017-09-30 | $1.12M | -51.57% |
| 2017-06-30 | $2.31M | - |
| 2017-03-31 | $2.31M | 49.92% |
| 2016-12-31 | $1.54M | - |
| 2016-09-30 | $1.54M | - |
Genfit generated $17.08M in revenue during Q4 2023, up 506.21% compared to the previous quarter, and up 321.71% compared to the same period a year ago.
Genfit Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| HRMY | Harmony Biosciences | $582.02M | $186.04M |
| GNFT | Genfit | $28.57M | $17.08M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| ADAG | Adagene | $18.11M | $833.34K |
| JANX | Janux Therapeutics | $8.08M | $1.25M |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| MNOV | MediciNova | $1.00M | - |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| ANTX | AN2 Therapeutics | - | - |
| AVTE | Aerovate Therapeutics | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| ACRV | Acrivon Therapeutics | - | - |
| ERYP | PHAXIAM Therapeutics | - | - |
| EWTX | Edgewise Therapeutics | - | - |
| CSBR | Champions Oncology | - | - |
GNFT Revenue FAQ
What is Genfit’s yearly revenue?
Genfit's yearly revenue for 2023 was $28.56M, representing an increase of 41.45% compared to 2022. The company's yearly revenue for 2022 was $20.2M, representing a decrease of -74.78% compared to 2021. GNFT's yearly revenue for 2021 was $80.07M, representing an increase of 10366.54% compared to 2020.
What is Genfit’s quarterly revenue?
Genfit's quarterly revenue for Q4 2023 was $17.08M, a 506.21% increase from the previous quarter (Q3 2023), and a 180.28% increase year-over-year (Q4 2022). The company's quarterly revenue for Q3 2023 was $2.82M, a -75.46% decrease from the previous quarter (Q2 2023), and a -46.93% decrease year-over-year (Q3 2022). GNFT's quarterly revenue for Q2 2023 was $11.48M, a 51.96% increase from the previous quarter (Q1 2023), and a 30.63% increase year-over-year (Q2 2022).
What is Genfit’s revenue growth rate?
Genfit's revenue growth rate for the last 3 years (2021-2023) was -64.32%, and for the last 5 years (2019-2023) was -7.37%.